Translational Medicine
Open Access
ISSN: 2161-1025
ISSN: 2161-1025
Department of Internal Medicine, Rush University Medical Center, Chicago, United States
Research Article
Inactivated SARS-CoV-2 Reprograms the Tumor Immune Microenvironment and Elicits Anti-Tumor Response in Melanoma and Triple Negative Breast Cancer Murine Model
Author(s): Eileena F Giurini, Michael Williams, Adam Morin, Andrew Zloza* and Kajal H Gupta*
Following the breakthrough of Immune Checkpoint Inhibitors (ICIs), a new era of immuno-oncology agents has
emerged and established immunotherapy as a part of cancer treatment. Despite the improving outcomes and
durability of response to ICIs, unfortunately many patients with initial response are known to develop acquired
resistance later. There is increasing interest in potentially using anti-pathogen immune response to induce an antitumor
immune response, which has led to rethinking into how the efficacy of anti-pathogen could be further
enhanced. The immunostimulatory effects of anti-pathogen treated tumors in combinations with ICI are known
to potentially amplify anti-tumor immunity resulting in increased tumor responses and improved outcomes. Antipathogen
treated tumors are immune-infiltrated “hot” tumors demonstrate higher treatment response rates.. View More»
DOI:
10.35248/2161-1025.22.12.268